Heidelberg Pharma 

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.